Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA — Stella

Home/Prostate Cancer/Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

View on ClinicalTrials.gov

Recruiting

Back to Prostate Cancer trials

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Penn State Cancer Institute, Hershey, Pennsylvania

Key details

Phase

Early testing / Safety & dosing

Sponsor

Milton S. Hershey Medical Center

Enrollment target

~45 participants

Started

May 2025

Primary completion

May 2027

Age range

40 Years and older

Sex

Male only

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.